ロード中...
Ceritinib as a promising therapy for ALK related diseases
Ceritinib, also known as LDK-378 or Zykadia (Novartis), is a second generation inhibitor able to specifically target the anaplastic lymphoma kinase (ALK). In the last five years the interest for ALK small inhibitors grew rapidly, mainly because it was discovered that a small but significant percenta...
保存先:
| 出版年: | Transl Lung Cancer Res |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Pioneer Bioscience Publishing Company
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367665/ https://ncbi.nlm.nih.gov/pubmed/25806325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.08.09 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|